![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Non-small cell lung cancer (NSCLC) consists of a class of heterogeneous diseases.
Objective: LncRNAs are exceedingly implicated in the pathogenesis of NSCLC. Herein, the current study set out to illustrate the molecular mechanism of SH3BP5-AS1 in NSCLC cells.
Methods: SH3BP5-AS1 expression in clinical NSCLC tissues and its impact on prognosis were analyzed by bioinformatics database. SH3BP5-AS1 expression patterns in NSCLC cell lines (A549/H1299/H1975/H460) and human normal lung epithelial cell lines (BEAS-2B) were examined by RT-qPCR. SH3BP5-AS1 was overexpressed in A549 or silenced in H1975 cells through transfection to assess its effect on proliferation, cell cycle distribution, and apoptosis, apoptosisrelated protein (Cleaved Caspase-3, Bax, Bcl-2) levels, invasive, migratory, and healing capacity through CCK-8, colony formation assay, flow cytometry, Western blot, Transwell, and cell scratch test.
Results: SH3BP5-AS1 was under-expressed in NSCLC clinical tissues, and NSCLC patients with low SH3BP5-AS1 expression showed poor prognosis. A549/H1299/H1975/H460 cells had reduced levels of SH3BP5-AS1, with the relative level lowest/highest expression in A549/H1975 cells, respectively. SH3BP5-AS1 overexpression repressed A549 cell proliferation, slowed down cell cycle progression, enhanced apoptosis, elevated Cleared Caspase-3, Bax, suppressed Bcl-2 protein levels, and inhibited migratory, invasive, and scratch healing capacities, while SH3BP5-AS1 silencing brought about the opposite results in H1975 cells.
Conclusion: SH3BP5-AS1 could suppress NSCLC cell proliferation, slow down cell cycle progression, stimulate apoptosis, and limit invasion and migration.
Keywords: Non-small cell lung cancer, SH3BP5-AS1, A549, H1975, cell proliferation, cell cycle, apoptosis, invasion, migration.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[http://dx.doi.org/10.1016/j.lungcan.2014.08.001] [PMID: 25172266]
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[http://dx.doi.org/10.3390/ijms222111701] [PMID: 34769131]
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]
[http://dx.doi.org/10.1016/j.apsb.2020.10.001] [PMID: 33643816]
[http://dx.doi.org/10.7754/Clin.Lab.2016.160812] [PMID: 28182363]
[http://dx.doi.org/10.3390/ncrna6030025] [PMID: 32629922]
[http://dx.doi.org/10.2147/OTT.S178431]
[http://dx.doi.org/10.3390/cancers14020439] [PMID: 35053601]
[http://dx.doi.org/10.3390/biom9090505] [PMID: 31546831]
[http://dx.doi.org/10.1007/s13258-021-01190-0] [PMID: 34783986]
[http://dx.doi.org/10.1186/s13062-022-00347-5] [PMID: 36397058]
[http://dx.doi.org/10.3389/fgene.2022.951311]
[http://dx.doi.org/10.1093/nar/gkx247] [PMID: 28407145]
[http://dx.doi.org/10.1259/bjr.20190524] [PMID: 31535580]
[http://dx.doi.org/10.1007/s11033-021-07066-6] [PMID: 35031926]
[http://dx.doi.org/10.1186/s12885-020-07755-8] [PMID: 33422052]
[http://dx.doi.org/10.1186/s12931-022-02043-4] [PMID: 35562727]
[http://dx.doi.org/10.1159/000519529] [PMID: 34525476]
[http://dx.doi.org/10.1016/j.canlet.2022.01.031]
[http://dx.doi.org/10.1186/s12890-020-01281-w] [PMID: 33081752]
[http://dx.doi.org/10.1186/1741-7007-11-59]
[http://dx.doi.org/10.1002/jcla.24302] [PMID: 35229919]
[http://dx.doi.org/10.18632/aging.204923] [PMID: 37566767]
[http://dx.doi.org/10.1158/0008-5472.CAN-22-1289] [PMID: 36214649]
[PMID: 35702078]
![Wayfinder Image](/images/wayfinder.jpg)